Neuphoria Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Sep 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 29, 2025
NEUP$2.69-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Other Comprehensive Income (Loss)
| Year Ended June 30, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| License revenue | $15,649,448 | $ | - |
| Operating expenses: | |||
| Research and development | 9,005,097 | 9,417,785 | |
| General and administrative | 7,773,442 | 8,474,591 | |
| Total operating expenses | 16,778,539 | 17,892,376 | |
| Loss from operations | (1,129,091) | (17,892,376) | |
| Other income (loss): | |||
| Interest income, net | 166,498 | 220,097 | |
| Loss on foreign currency transactions | (414,996) | (209,842) | |
| Research and development incentive award | 299,905 | 95,215 | |
| Gain on fair value adjustments | 239,686 | 2,207,420 | |
| Total other income | 291,093 | 2,312,890 | |
| Loss before income tax benefit | (837,998) | (15,579,486) | |
| Income tax benefit | 468,366 | 87,320 | |
| Net loss | (369,632) | (15,492,166) | |
| Other comprehensive income: | |||
| Unrealized gain on foreign currency translation | 168,529 | 45,188 | |
| Total other comprehensive income | 168,529 | 45,188 | |
| Total comprehensive loss | $(201,103) | $(15,446,978) | |
| Net loss per share - basic and diluted | $(0.23) | $(18.62) | |
| Weighted-average common shares outstanding - basic and diluted | 1,622,924 | 832,225 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.